StockData
Stevanato Group S.p.A. logo

Stevanato Group S.p.A. (STVN) company profile

STVNNYSESurgical & Medical Instruments & Apparatus
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 4, 2026Score 8/30
$15.25−0.28 (-1.80%)

Close on Nov 17, 2026Market cap $4.62BP/E 27.1Yield –

About Stevanato Group S.p.A.

Surgical & Medical Instruments & Apparatus, SIC 3841

Stevanato Group S.p.A. provides drug containment, drug delivery, and diagnostic solutions, alongside manufacturing engineering systems for the pharmaceutical, biotechnology, and life sciences industries. It operates through two primary segments: Biopharmaceutical and Diagnostic Solutions, which supplies products such as pre-fillable syringes, vials, cartridges, diagnostic consumables, and drug delivery devices; and Engineering, which designs visual inspection, assembly, packaging, and serialization machinery. The company primarily serves global pharmaceutical, biotechnology, and diagnostic businesses, supporting their drug product life cycles from research through commercial production.

Headquartered in Piombino Dese (Padua), Italy, the company distributes its products and services across approximately 65 countries worldwide. Its global infrastructure includes 13 manufacturing plants, comprising ten production facilities for biopharmaceutical and healthcare products and three plants dedicated to equipment and machinery, located in Italy, Germany, Slovakia, Brazil, Mexico, China, Denmark, and the United States. In addition, the firm maintains two analytical testing sites and five commercial offices globally.

Summary of the business section of Stevanato Group S.p.A.'s latest annual report, written by StockData.

Company profile

Company

Legal name
Stevanato Group S.p.A.
Founded
1949
Headquarters
Padua, Italy
Address
Piombino Dese (Pd) Via Molinella, 17 35017
Phone
39 049 9318173
Employees
6,010, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Auditor
PricewaterhouseCoopers SpA, Treviso, Italy

Stock & identifiers

Ticker
STVN
Exchange
NYSE
IPO date
Jul 16, 2021
Shares outstanding
303M, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1849853
CUSIP
T9224W109
FIGI
BBG001RY95L9
Share class FIGI
BBG001V2NPF1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Franco StevanatoChief Executive Officer, Director–
Mauro StocchiSee Remarks400,000
Lago Marco DalChief Financial Officer81,144
William J. FedericiDirector78,580
Donald E. Morel JrDirector62,424
Elisabetta MagistrettiDirector2,930
Luciano SantelDirector4,739
Karen FlynnDirector5,757
Madhavan BalachandranDirector69,458
Sue-Jean LinDirector6,975
Alvise SpinazziDirector3,300
Fabrizio BonanniDirector119,700
Sergio StevanatoDirector253,238,887

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 16, 2021
Offer price
$21.00
Exchange
NYSE
First trading day
Jul 16, 2021
First-day close
$19.67-6.3%
Lock-up ends (est.)
Jan 12, 2022

“The initial public offering price is $21.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 6,010 employees in multiple jurisdictions (approximately 58% based in Italy, 10% based in Germany, 8% based in the U.S., 7% based in Mexico, 5% based in Brazil, 4% based in each Slovakia, and Denmark, and 3% based in China).”

Corporate history

Events identified from SEC filings

See a number that looks wrong?